Doctor Sukrut Shah
Rahway (United States of America)
A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C
Event: ESC Congress 2016
Topic: Drug therapy
Session: Lipid-lowering agents - New perspectives
ESC 365 is supported by
